Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel): Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.
8 min read
AAVB-081 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
AAVB-081: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EX-103 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
EX-103: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
AZD-8421 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
AZD-8421: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
EG110A Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
EG110A: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
WTX-330 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
WTX-330: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
PMD-026 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
PMD-026: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
HP-518 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
HP-518: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Wharton's Jelly Mesenchymal Stem Cell(PT. Prodia Stem Cell Indonesia) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Wharton's Jelly Mesenchymal Stem Cell(PT. Prodia Stem Cell Indonesia): Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.
8 min read
TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes(NCI) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes(NCI): Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical.
8 min read
TB31F Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
TB31F: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
LYT-200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
LYT-200: Phase 1/2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key.